UBS Group
CLDX icon

UBS Group’s Celldex Therapeutics CLDX Stock Holding History

UBS Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-40,000
Closed -$1.08M – 10397
2022
Q2 		$1.08M Buy
+40,000
New +$1.16M ﹤0.01% 3672
2016
Q1 		– Sell
-80
Closed -$19K – 7678
2015
Q4 		$19K Sell
80
-7
-8% -$1.53K ﹤0.01% 6796
2015
Q3 		$14K Sell
87
-26
-23% -$7.36K ﹤0.01% 7005
2015
Q2 		$43K Buy
113
+13
+13% +$5.16K ﹤0.01% 6120
2015
Q1 		$42K Sell
100
-413
-81% -$148K ﹤0.01% 6214
2014
Q4 		$141K Buy
+513
New +$128K ﹤0.01% 5348

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

UBS Group's CLDX Position: Q3 2026 in Review

UBS Group increased its Celldex Therapeutics (CLDX) stake by 93% in Q3 2026, buying an estimated $17.1M and bringing the position to 929,277 shares worth $30.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2211.

UBS Group first reported a position in CLDX in Q4 2014 and has held it in 48 quarters since. 166 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • UBS Group held 929,277 shares of Celldex Therapeutics worth $30.1M as of Q3 2026.
  • UBS Group bought 447,280 Celldex Therapeutics shares in Q3 2026, an estimated $17.1M.
  • Celldex Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #2211 holding.
  • UBS Group first reported a position in Celldex Therapeutics in Q4 2014 and has held it in 48 quarters since.
  • 166 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.